Khan Najat's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Dec 29, 2025
- Accession no.
- 0001601830-25-000176
- Filed
- Dec 29, 2025
- Trade date
- Dec 22, 2025
- Filing delay
- 7 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $548.6K. It was filed 7 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Khan NajatCIK 0002020969 | Director, Officer (Chief R&D Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 22, 2025 | Class A Common Stock | SSaleDisposed | −124,403 | $4.41F2 | −$548,617.23 | 611,135 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $4.30 to $4.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.